Cholangiocarcinoma Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

Cholangiocarcinoma Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

Report Format: PDF+Excel | Report ID: SR112025A6424

Market Overview: 

The cholangiocarcinoma market reached a value of USD 1,043.0 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 2,886.3 Million by 2035, exhibiting a growth rate (CAGR) of 9.71% during 2025-2035.

Report Attribute
Key Statistics
Base Year  2024
Forecast Years  2025-2035
Historical Years 
2019-2024
Market Size in 2024
USD 1,043.0 Million
Market Forecast in 2035
USD 2,886.3 Million
Market Growth Rate 2025-2035
9.71%


The cholangiocarcinoma market has been comprehensively analyzed in IMARC's new report titled "Cholangiocarcinoma Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Cholangiocarcinoma market is currently driven by factors such as a rising geriatric population, increasing number of patients with liver disease, a large smoking population, growing number of patients with diabetes, and rising safety and efficacy of current and emerging therapies, etc. Furthermore, the introduction of technologically advanced diagnostics that assist in monitoring tumour progression, assessing therapeutic response and clinical prognosis, and detecting recurrent tumours is further creating a positive outlook for the market.

Cholangiocarcinoma is a type of cancer involving the mutation of epithelial cells in the bile ducts. Some of the common factors responsible for the disease development include prolonged inflammation in the liver, biliary stones, abnormalities in the bile duct such as cysts, infection caused due to liver flukes parasite, and exposure to harmful chemicals and toxins. It occurs mostly in people over 65 years, though it may occur at any age. Cholangiocarcinoma is also slightly more common in men compared to women. The indication usually does not cause symptoms till it reaches an advanced stage and has spread to other organs and tissues. Few patients may, however, experience early symptoms. These may involve the yellowing of the skin and the whites of the eyes, itchiness of skin, light-colored stool, pain/bloating in the stomach, nausea and vomiting, loss of appetite/unexplained weight loss, fever, and fatigue.

IMARC Group's new report provides an exhaustive analysis of the cholangiocarcinoma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for cholangiocarcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cholangiocarcinoma market in any manner.

Time Period of the Study

  • Base Year: 2024
  • Historical Period: 2019-2024
  • Market Forecast: 2025-2035

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan

Analysis Covered Across Each Country

  • Historical, Current and Future Epidemiology Scenario
  • Historical, Current and Future Performance of the Cholangiocarcinoma Market
  • Historical, Current and Future Performance of Various Therapeutic Categories in the Cholangiocarcinoma Market
  • Sales of Various Drugs Across the Cholangiocarcinoma Market
  • Reimbursement Scenario in the Cholangiocarcinoma Market

Competitive Landscape:

This report also provides a detailed analysis of the current Cholangiocarcinoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
Drugs Company Name
GNS561 Genoscience
ABC294640 RedHill Biopharma


*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

  • How has the cholangiocarcinoma market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
  • What was the country-wise size of the cholangiocarcinoma across the seven major markets in 2024 and what will it look like in 2035?
  • What is the growth rate of the cholangiocarcinoma across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?

Epidemiology Insights

  • What is the number of incident cases (2019-2035) of cholangiocarcinoma across the seven major markets?
  • What is the number of incident cases (2019-2035) of cholangiocarcinoma by age across the seven major markets?
  • What is the number of incident cases (2019-2035) of cholangiocarcinoma by gender across the seven major markets?
  • What is the number of incident cases (2019-2035) of cholangiocarcinoma by type across the seven major markets?
  • How many patients are diagnosed (2019-2035) with cholangiocarcinoma across the seven major markets?
  • What is the size of the cholangiocarcinoma patient pool (2019-2024) across the seven major markets?
  • What would be the forecasted patient pool (2025-2035) across the seven major markets?
  • What are the key factors driving the epidemiological trend cholangiocarcinoma of?
  • What will be the growth rate of patients across the seven major markets?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for cholangiocarcinoma drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cholangiocarcinoma market?
  • What are the key regulatory events related to the cholangiocarcinoma market?
  • What is the structure of clinical trial landscape by status related to the cholangiocarcinoma market?
  • What is the structure of clinical trial landscape by phase related to the cholangiocarcinoma market?
  • What is the structure of clinical trial landscape by route of administration related to the cholangiocarcinoma market?

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Cholangiocarcinoma Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035
Purchase Options Discount
Offer
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-201-971-6302

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials